Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy 
The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present) 
Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry 
Must have a life expectancy of greater than three (3) months 
Karnofsky Performance Status > 60 
Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.) 

NCT00050349_inc_T1
Condition
metastatic carcinoid tumors
NCT00050349_inc_T2
Value
proven
NCT00050349_inc_T3
Procedure
biopsy
NCT00050349_inc_T4
Condition
other neuroendocrine tumors
NCT00050349_inc_T5
Condition
Islet cell
NCT00050349_inc_T6
Condition
Gastrinomas
NCT00050349_inc_T7
Condition
VIPomas
NCT00050349_inc_T8
Scope
Islet cell, Gastrinomas and VIPomas
NCT00050349_inc_T9
Condition
measurable lesion
NCT00050349_inc_T10
Qualifier
bone
NCT00050349_inc_T11
Scope
biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas)
NCT00050349_inc_T12
Procedure
irradiated
NCT00050349_inc_T13
Procedure
irradiated
NCT00050349_inc_T14
Observation
progression
NCT00050349_inc_T15
Procedure
radiation therapy
NCT00050349_inc_T16
Temporal
since the radiation therapy
NCT00050349_inc_T18
Negation
not been
NCT00050349_inc_T17
Scope
not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy
NCT00050349_inc_T19
Condition
major impairment of renal function
NCT00050349_inc_T20
Condition
major impairment of hepatic function
NCT00050349_inc_T21
Negation
no
NCT00050349_inc_T22
Scope
major impairment of renal or hepatic function
NCT00050349_inc_T23
Measurement
total bilirubin
NCT00050349_inc_T24
Value
<1.5 X ULN
NCT00050349_inc_T25
Measurement
AST
NCT00050349_inc_T26
Measurement
ALT
NCT00050349_inc_T27
Value
<2.5X ULN
NCT00050349_inc_T28
Condition
liver metastases
NCT00050349_inc_T29
Value
<5 X ULN
NCT00050349_inc_T30
Scope
AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)
NCT00050349_inc_T31
Scope
total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present)
NCT00050349_inc_T32
Drug
Sandostatin Lar
NCT00050349_inc_T33
Drug
long acting somatostatin analogue
NCT00050349_inc_T34
Qualifier
stable dose
NCT00050349_inc_T35
Temporal
for 30 days prior to study entry
NCT00050349_inc_T36
Drug
short acting somatostatin analogues
NCT00050349_inc_T37
Qualifier
clinically stable dose
NCT00050349_inc_T38
Temporal
prior to study entry
NCT00050349_inc_T39
Observation
life expectancy
NCT00050349_inc_T40
Value
greater than three (3) months
NCT00050349_inc_T41
Measurement
Karnofsky Performance Status
NCT00050349_inc_T42
Value
> 60
NCT00050349_inc_T43
Person
Female
NCT00050349_inc_T44
Measurement
serum pregnancy test
NCT00050349_inc_T45
Value
negative
NCT00050349_inc_T46
Temporal
at screening
NCT00050349_inc_T47
Procedure
bilateral oophorectomy
NCT00050349_inc_T48
Procedure
hysterectomy
NCT00050349_inc_T49
Condition
postmenopausal
NCT00050349_inc_T51
Scope
bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal
NCT00050349_inc_T50
Scope
bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal
NCT00050349_inc_T52
Scope
negative serum pregnancy test at screening
NCT00050349_inc_T53
Reference_point
radiation therapy
NCT00050349_inc_T54
Negation
other than